(Total Views: 506)
Posted On: 07/26/2025 1:58:59 PM
Post# of 155808
I know folks here don’t care to hear from ChatGPT, but I asked about the S-3. Here is the short answer:
Bottom line
The new $100 M Form S-3 is effectively a clean slate—the 2021 shelf it “coincides” with is gone, so there’s no overlap in capacity. Going forward, every primary financing CytoDyn does will come off this 2025 shelf (and within the baby-shelf limits) until it either a) exhausts the $100 M aggregate, b) hits the one-third-of-float ceiling over the next year, or c) the shelf itself expires in mid-2028.
Bottom line
The new $100 M Form S-3 is effectively a clean slate—the 2021 shelf it “coincides” with is gone, so there’s no overlap in capacity. Going forward, every primary financing CytoDyn does will come off this 2025 shelf (and within the baby-shelf limits) until it either a) exhausts the $100 M aggregate, b) hits the one-third-of-float ceiling over the next year, or c) the shelf itself expires in mid-2028.
(15)
(0)
